Pilotstudie carvedilol äs vasodilating β-blocker for the treatment of hypertensive patients with peripheral vascular disease - a pilot study;Carvedilol als vasodilatierender β-Rezeptorblocker bei Patienten mit Hypertonie und peripherer arterieller Verschlusskrankheit - Eine

Herz Kreislauf

Volumn 32, Issue 2, 2000, Pages 69-73

  Bauriedel, G ^a   Skowasch, D ^a   Hofling B ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

receptor blocker; Carvedilol; Hypertension; Peripheral vascular disease

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERANCE; DYSPNEA; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; MALE; PERIPHERAL VASCULAR DISEASE; VASOCONSTRICTION; VASODILATATION; WALKING;

EID: 0033955889     PISSN: 00467324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvediol. a vasodilatoi-fi-blocker, in patients with congestive heart failure due to ischémie heart disease. Circulation 1995, 92:212-8
2. Böhmeke T, Weber K. van der Does R, Mocker B, Ricken D. Akute und subchronische kaidiovaskulare Effekte des vasod/latierenden Betabiockers Carvediol im Vergleich zu Meloprool in der Therapie der arteriellen Hypertonie Heiz/Kresl 1994; 26. 22-6.
3. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman NH, for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventriculai function und survival in subjects with chronic lieurt failure. Circulation 1996:94 2807-16.
4. A Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN. Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA, for the US Carvedilol Heart Failure Study Group. Carve ciilol inhibits clinicnl progression in patients with mild symptoms of heart failure Circulation 1996, 94' 2800-6.
5. Heber ME. Bridgen GS, Caruana MP. Lahiri A, Raftery EB. Caivedilol for systemic hypertension. Am j Cardiol 1987, 5V: 400-5.
6. Hiatt WR, Stoll S, Nies AS. Effect offi-adreneigic tiockers on the peripheral circulation in patients with peripheral vascular disease. Circulation 1985; 72; 1226 31.
7. Lund-Johansen P, Omvik P, Nordrehaug JE. White W. Carvediol in hypertension' Effects of hemodynamics and 24-hour blood pressure. J Car diovasc Phaimacol 1992. 19 (Suppl. 1). 27-34
8. Mauser M, Voelker W, Ickrath O, Hoffmeister HM, Karsch KR. Hàmodynamische Akuteffekte des neuen vasoüilatiei enden Betabiockers Caivedilol im Vergleich tu komhineiten Gabe von Nifedi p/n und Piopranolol hei Patienten mit koronarei Heizeikiankung Z Kaidiol 1989. 78. 726-31
9. McPhillips JJ. Schwemer GT, Scott Dl, Zinny M, Patterson D. Effects of caivedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. Drugs 1988: 36 (Suppl 6): 82-91.
10. Meyer-Sabellek WA, Schulte KL, Thiede HM, Götzen R. Acute hypotensive lesponse to the new antihypertensive agent BM 14190 in essential hypertensive patients j Hypeitens 1983, 1 (Suppl. 2): 351-2.
11. Morgan T, Snowden R, Butcher L. Effect of cai vedilol and metopio/ol on blood piessure. blood flow and vascular res/stence J Cardiovasc Pharma col 1987; W (Suppl. 111. 124-9.
12. Ohlstein EH, Douglas SA, Sung CP, Vue TL, Louden C, Arleth A, Poste G, Ruffolo RR, Feuerstein GZ. Cmvedilol. a cardiovascular iliug. prevents vascular smooth muscle cell pioliferntion. migiation. and neointimal formation following vascular injury. Pioc NatlAcadSci USA 1993: 90: 0189-93
13. Packer M, Bristow MR, Conn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group. Effect of caivedilol on morbidity and mortality in chronic heart failure N Engl j Med 1996, 334. 1349 55.
14. Rittinghausen R. Response late with respect to the blood pressure lowering effect of the vasodilating and u-blocking agent caivedilol Drugs 1988, 36 (Suppl. 6): 92 101.
15. Rodrigues EA, Lahiri A, Hughes LO, Kohli RS. Whittington JR, Raftery EB. Antiangmal efficacy of carvedilol. a beta-blocking drug with vnsolilatng activity Am J Curdiol 1986, 58: 916-21
16. Schweizer J, Kaulen R, Altmann E. Nierade A, Nanning T. Sind etablocker bei Patienten mit pen-pherei arterieller Verschlukrankheit yenernl kon traindizierV Z Kardiol 1996:85 193 7
17. Solomon SA, Ramsay LE, Yeo WW. Beta bnckade and intermittent claudication, placebo controlled trial ofatenool and mfedipine and their combination. BMJ 1991, 303. Il00-4.
18. Swedsen TL, Jelnes R, Tonnesen KH. Tht effects of acebutool and metoprolol on walking dstances and distal blood pressure in hypertensive natients with intermittent claudication. Acta Med Scand 1986:219 16l-5.
19. Yoshikawa T, Port JD, Asano K. Chidiak P. Bouvier M, Dutcher D, Roden RL, Minobe WA, Tremmel RD, Bristow MR. Cmdiac adnergic receptor effects of caivediol. Eur Hem t J 1.196: 178-16.
20. Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R. Gu JL, Lysko KA, Davis LL, Feuerstein GZ. Carvedilol. a new vasodilatoi and beta adrenoceptor antagonist, is an antioxidant and fiée radical scavenger. J Phaimacol Exp Ther 1992: 263. 92 0